{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/neuropathic-pain-drug-treatment/prescribing-information/tramadol/","result":{"pageContext":{"chapter":{"id":"01a263c7-9fe1-5a29-95ec-24e56c0c1bc9","slug":"tramadol","fullItemName":"Tramadol","depth":2,"htmlHeader":"<!-- begin field 14ecf768-dd7c-44c8-97b0-a65030a532b7 --><h2>Tramadol</h2><!-- end field 14ecf768-dd7c-44c8-97b0-a65030a532b7 -->","summary":"","htmlStringContent":"<!-- begin item 83ea4b0e-5ec2-4f55-868d-94eb50ff4a9b --><!-- end item 83ea4b0e-5ec2-4f55-868d-94eb50ff4a9b -->","topic":{"id":"b1f9c908-6cb6-5afd-a737-0a621c6232d0","topicId":"35e3d915-8243-4418-a7dd-6590d8ca5c85","topicName":"Neuropathic pain - drug treatment","slug":"neuropathic-pain-drug-treatment","lastRevised":"Last revised in December 2020","chapters":[{"id":"0c243e96-3697-5ee3-98c7-9ffecf07f2af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94d784c6-0537-5187-a548-a95e6ad2f899","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"855f03f8-54cb-5675-a6b8-aeb8064288d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f0b9b63a-bd52-51b6-8eda-cb26c9f551a0","slug":"changes","fullItemName":"Changes"},{"id":"2e3e3fff-20af-56ab-b8f8-a9ee4f14f833","slug":"update","fullItemName":"Update"}]},{"id":"80218328-d006-5b34-a01a-0ef4dbeaf7d5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"22989c5e-df85-5aba-bd66-8c44723e59d7","slug":"goals","fullItemName":"Goals"},{"id":"722de221-9258-5985-8a02-c088cf258a12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bf3b0c22-2d82-5464-bf76-bc066dae256f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c6576f2f-fd04-5900-a5e1-517233523e2c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd2de31a-79d5-5c20-9132-c99c41c12822","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"148cc621-37d8-5264-a358-c380fcfb4223","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"eddf36b3-7bc8-53c9-9c59-fa36b809f229","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025ef443-81b5-565d-8240-d76615c27e55","slug":"definition","fullItemName":"Definition"},{"id":"3704349e-d3ae-5a8b-ba94-9da5282ed77f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e18339e8-95d0-582f-ad51-0614dae8f855","slug":"complications","fullItemName":"Complications"},{"id":"9b552f08-01aa-583d-900b-9cbdc90fe28d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"21d7485a-b855-5ba4-82bc-ca3154184325","fullItemName":"Management","slug":"management","subChapters":[{"id":"bad22859-57ae-5c1c-a944-c3d9fef6d160","slug":"neuropathic-pain-drug-treatment","fullItemName":"Scenario: Neuropathic pain - drug treatment"}]},{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a91a8f28-db46-58e8-9df7-f30be0f00f2b","slug":"amitriptyline","fullItemName":"Amitriptyline"},{"id":"382b9603-7b46-57d1-9b07-fa743886796e","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"498f1249-e619-5b41-b42b-1a914239d269","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"201a6fcc-11c6-5f00-b820-7fa69ee8b95d","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"56e4231d-ab93-5963-bc8a-989240189179","slug":"capsaicin-cream","fullItemName":"Capsaicin cream"},{"id":"01a263c7-9fe1-5a29-95ec-24e56c0c1bc9","slug":"tramadol","fullItemName":"Tramadol"}]},{"id":"9ed9a9fb-0b52-50ef-8980-c1303531094d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4fd6ab13-09e0-57f4-a265-464eeab8c835","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3eb7f136-ffd0-5f27-b2d1-21b49247596d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"606fc7bf-da44-5385-95f8-0139b3c57ef7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9fc3997f-80c3-5333-b5bd-3b3a518bdde6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"74708745-26ce-5fd4-8c02-67ba25b5a355","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f5855b4-c905-54ca-b02a-820f8fdd4a4a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f09723db-fe39-5bbd-b643-d063fcd61d42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"365aad7d-781d-58ad-baa7-d7c9bd2e3bd8","slug":"licensed-indication","fullItemName":"Licensed indication","depth":3,"htmlHeader":"<!-- begin field 7ccb1613-d10e-4113-99dd-ab5601099ccd --><h3>Is tramadol licensed for neuropathic pain?</h3><!-- end field 7ccb1613-d10e-4113-99dd-ab5601099ccd -->","summary":"","htmlStringContent":"<!-- begin item e8862693-bb0d-4631-8817-ab5601099c9a --><!-- begin field d9f38132-eeb0-4830-bc0d-ab5601099ccd --><ul><li>Although not specifically licensed for the neuropathic pain, tramadol is licensed for the treatment of moderate to severe pain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020e</a>]. </li><li>The National Institute for Health and Care Excellence (NICE) recommends tramadol for people with neuropathic pain (except trigeminal neuralgia), only if acute rescue therapy is needed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">NICE, 2019a</a>]. </li></ul><!-- end field d9f38132-eeb0-4830-bc0d-ab5601099ccd --><!-- end item e8862693-bb0d-4631-8817-ab5601099c9a -->","subChapters":[]},{"id":"c1f83200-a649-584d-abae-1a8c23867a3e","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 2eb19b41-c828-4248-9c99-ab56010904a8 --><h3>Dose and titration</h3><!-- end field 2eb19b41-c828-4248-9c99-ab56010904a8 -->","summary":"","htmlStringContent":"<!-- begin item 8828bca0-ed93-4a08-ae74-ab5601090415 --><!-- begin field 898ccc6c-155b-4aff-bc82-ab56010904a8 --><ul><li>The dose of tramadol is 50 to 100 mg not more often than every 4 hours (up to a maximum of 400 mg a day) titrated according to the pain severity.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020e</a>]</p><!-- end field 898ccc6c-155b-4aff-bc82-ab56010904a8 --><!-- end item 8828bca0-ed93-4a08-ae74-ab5601090415 -->","subChapters":[]},{"id":"c4cff233-00cb-5101-aeab-1ed14cbf942e","slug":"prescribing-issues","fullItemName":"Prescribing issues","depth":3,"htmlHeader":"<!-- begin field 2e429fda-d3d8-4cf0-a505-d355ae350057 --><h3>Other prescribing issues</h3><!-- end field 2e429fda-d3d8-4cf0-a505-d355ae350057 -->","summary":"","htmlStringContent":"<!-- begin item 60344081-cd98-44f3-b054-dbe573e8bef8 --><!-- begin field 959dcd0a-66e3-4ba0-b6c1-14964f49ac28 --><h4>Legal issues</h4><ul><li>Tramadol is a controlled drug and as such is subject to the legal requirements associated with controlled drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Home Office, 2014</a>].</li></ul><h4>Other prescribing issues</h4><ul><li>For further information on how to prescribe tramadol, including contraindications and cautions, adverse effects, drug interactions, and monitoring, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li></ul><!-- end field 959dcd0a-66e3-4ba0-b6c1-14964f49ac28 --><!-- end item 60344081-cd98-44f3-b054-dbe573e8bef8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}